Precision Medicine Initiative (PMI) Committee Meeting

July 12, 2023

NIH NATIONAL CANCER INSTITUTE

Agenda

- Role Call
- Project Status Updates
  - Walk through EC Template v2.0
- Group Project Status Updates
- Project Discussion Items
- Review FAQs
- Next Steps

Stakeholder Representation



Project Status Updates

Project Updates

PMI Project Deliverable	Targeted Release Date	Release Vehicle
ComboMATCH changes (Disease fields, histology, behavior field code)	July 17, 2023	Screening Protocol EC Template v2.0
Designated Labs for Combo	July 31, 2023	Screening Protocol EC Template v3.0
Re-Screening ComboMATCH	August 18, 2023	Screening Protocol Re-Screening EC Template v1.0
MyeloMATCH Tx Protocol Crossover (for S01, CTG01 and EA02)	September 18, 2023	Part of the existing Treatment Protocol workflow.
Cohort Migration	September 25, 2023	Treatment Protocol EC Template v2.0
Re-Screening MM	Oct 10, 2023	Screening Protocol Re-Screening EC Template v2.0
STMF	Oct 16, 2023	PMI Screening Protocol ALS v2.0
CLIA	Oct 16, 2023	PMI Screening Protocol ALS v2.0
Path	Oct 16, 2023	PMI Screening Protocol ALS v2.0
PMI Screening Protocol ALS v2.0	~ mid-October 2023	Target to start Group Beta UAT

EC Screening Template Release Schedule

Release	Details	Tentative Release Date
V1.0	Production Release	February 15th 2023
V2.0	Includes CM changes (Disease fields, histology, behavior field code)	July 17th 2023
V3.0	Includes updates for Designated Labs (DLAP fields)	August 18th 2023
V4.0	MM MSRP changes	TBD *Verify if SWOG start their build with all the other fields and add the new field in when the update goes out? {7/12 – Have an older version, would like a little over a month before activation, 2 months would be ideal)*

PMI Screening Protocol EC Template v2.0

PMI EC CDE PID	PMI EC Question Text (QT)/Prompt	Combo MATCH	Myelo MATCH	OPEN Widget Type	Notes
Miscellaneous Module					
7063912	**ECOG performance status**	Mandatory	Mandatory	Radio Group Vertical	Assists in determining potential treatment assignment for a patient.
2178058	**Hormone Receptor Status**	Mandatory	*Optional*	Radio Group Vertical	
2185607	**HER2 Status**	Mandatory	*Optional*	Radio Group Vertical	
Physician's Choice Module					
10987207	**Treatment protocol assignment details**	Mandatory	*Optional*	Group Lookup List	The Physician may recommend a preferred protocol treatment assignment for a patient.
7765280	**Clinical justification**	Mandatory	*Optional*	Text Area	
Patient Fitness Module					
12100429	**Is the patient fit for intensive chemotherapy?**	*Optional*	Mandatory	Radio Group Vertical	The Physician's determination of a patient's fitness for potential intensive or non-intensive chemotherapy treatment assignment. .
DLAP Module					
12053081	**LAB internal tracking ID**	Mandatory	*Optional*	Edit Box	Supports the PMI Designated Lab Automation Program (DLAP) integration. The DLAP Scenario ID field is mandatory to be on the EC form but may be left blank by the site user; site entry is based on if the data has/hasn't yet been confirmed in DLAP. *[Processing laboratory name - Non-enumerated field added, previously an enumerated field.]*
12932659	**Processing laboratory name**	Mandatory	*Optional*	Group Lookup List	
8177505	**DLAP Scenario ID**	Mandatory	*Optional*	Edit Box	
Drug & Disease Service Module 1 (disease): these fields support the PMI Disease Service integration.					
10948385	**Topography**	Mandatory	*Optional*	Type Ahead List	Populated by the disease service with an ICD-O-3 topography site/subsite.
10948388	**Histology**	Mandatory	*Optional*	Type Ahead List	Populated by the disease service with a histology code. *[Separate field added, previously 1 'Histology' field.]*
13345476	**Tumor Behavior Code**	Mandatory	*Optional*	Type Ahead List	Captures the behavior code. *[Separate field added, previously 1 'Histology' field.]*
10983888	**Grade**	Mandatory	*Optional*	Radio Group Vertical	Captures the grade or level of differentiation of malignant neoplasms.
Drug & Disease Service Module 2 (drug): this field supports the PMI Drug Service integration.					
10984702	**Prior therapy name**	Mandatory	Mandatory	Type Ahead List	Populated with pharmacological substance/drug details per the NCI Thesaurus. Twenty occurrences of this CDE are specified in the PMI CDISC Screening Protocol EC Template.

PMI Form Mappings

Group	Status Update
Alliance	Pending, finalization & meetings scheduled with Leadership for week of 07/17/2023.
COG	Pending finalization, will be sent end of week 07/10/2023.

Group Project Status Updates

Group Testing Updates CM

Group	EC Template			Central Study ALS		Screening Protocol ALS		Treatment Protocol ALS		Screening/Treatment Test Cases (%done)		
	caDSR II (Y/N)	EC Build in Rave (Y/N)	Target Completion Date	Completed Upload (Y/N)	Target Completion Date	Completed Upload (Y/N)	Target Completion Date	Completed Upload (Y/N)	Target Completion Date	Initiated Beta UAT (Y/N)	Group Test Cases (%)	Target Completion Date
ECOG-ACRIN	Screening (Y) Treatment (Y)	Screening (Y) Treatment (Y)	1/27/23	v1.0- Yes v1.0.1.0 - Yes	1/20/2023	100%	1/18/2023	100%	1/18/2023	Screening (Y) Treatment (100) – E4 E5 – In Progress	Screening (100%) Treatment (100%)	Screening 2/01/2023 Treatment 2/01/2023
SWOG (S3)	Yes	Yes	1/20/2023	v1.0- Yes v1.0.1.0 - Yes	1/20/2023	N/A		Complete	Complete	Complete	Complete	Complete
NRG (N2, N4)	Yes	N4 - Completed N2 – Completed	1/27/2023 1/31/2023	v1.0- Yes v1.0.1.0 - Yes	1/25/2023	N/A	N/A	Complete		Treatment (Y)	Complete	2/2/2023
Alliance (A6, A3, A2)	Yes	A6 – Yes A3 – In Process A2 – In Process to adding Cohort Migration	1/25/2023 Starting with A3 first	v1.0- Yes v1.0.1.0 - Yes	1/25/2023	N/A	N/A	Complete		Treatment (Y)	Treatment (100%)	3/1/2023
COG (C1) – Submitted Protocol	No	New Version (N)	2/24/2023	v1.0- Yes v1.0.1.0 – Yes	2/01/2023	N/A	N/A	Complete		Treatment (N)	Treatment (0%)	03/31/2023

Group Testing Updates - MM

Group	EC Template			Central Study ALS		Screening Protocol ALS		Treatment Protocol ALS		Screening/Treatment Test Cases (%done)		
	caDSR II (Y/N)	EC Build in Rave (Y/N)	Target Completion Date	Completed Upload (Y/N)	Target Completion Date	Completed Upload (Y/N)	Target Completion Date	Completed Upload (Y/N)	Target Completion Date	Initiated Beta UAT (Y/N)	Group Test Cases (%)	Target Completion Date
SWOG **S01, S02**	Screening (Y) Treatment (Y)	Current Version (Y) Screening New Version (N) S01 – Built S02 – Priority 2	1/20/2023	v1.0- Yes v1.0.1.0 - Yes	1/20/2023	50%	Pending	Pending	Pending	Screening (N) Treatment (N)	Screening (N) Treatment (N)	
ECOG-ACRIN 02, 01, 03	Y	EA02 – Have a solid Rave Build, but waiting on EC Checklist	Completed	v1.0- Yes v1.0.1.0 - Yes	1/20/2023	N/A	N/A	100%	1/18/2023	In Progress		
CCTG G01	Y	Current Version (Y) New Version (N)	1/30/2023	v1.0- Yes v1.0.1.0 - Yes	1/25/2023	N/A	N/A	Completed		Treatment (N)	Treatment (0%)	Treatment TBD

CM Internal UAT Testing Updates

Group	Internal UAT	Prod Screening Protocol ALS		Prod Treatment Protocol ALS	
	Progress (% Complete)	*Completed Upload (Y/N)*	*Target Completion Date*	*Completed Upload (Y/N)*	*Target Completion Date*
ECOG-ACRIN	95% 80%	Ran a diff report, used existing version and matched production version (Y)		Imported Central Study, Ran a diff report, used existing version and matched production version (Y)	
SWOG	100%	N/A	N/A	Imported Central Study, Used diff report, used existing version and matched production version (Y)	
NRG	N4 - 100% N4 – 100%	N/A	N/A	Imported Central Study, Used diff report, used existing version and matched production version (Y)	
Alliance	100% (CM) *Will need to retest based on new workflow	N/A	N/A	Imported Central Study, Used diff report, used existing version and matched production version (Y)	
CCTG	100%	N/A	N/A		
COG		N/A	N/A		

MM Internal UAT Testing Updates

Group	Internal UAT	Prod Screening Protocol ALS		Prod Treatment Protocol ALS	
	Progress (% Complete)	*Completed Upload (Y/N)*	*Target Completion Date*	*Completed Upload (Y/N)*	*Target Completion Date*
ECOG-ACRIN	80%	Ran a diff report, used existing version and matched production version (Y)		Imported Central Study, Ran a diff report, used existing version and matched production version (Y)	
SWOG	Waiting on new EC Template			Imported Central Study, Used diff report, used existing version and matched production version (Y)	
NRG	N/A	N/A	N/A	N/A	
Alliance		N/A	N/A	Imported Central Study, Used diff report, used existing version and matched production version (Y)	
CCTG	Have not done OPEN integration Testing for MM – Need Patients – Pending MSRP Build (v2 of EC Template will follow up online)	N/A	N/A		
COG	N/A	N/A	N/A	N/A	

ComboMATCH/MM FFP Testing Updates

Group	Enrollment Forms *Finalized Enrollment Forms (EC forms and Rave Treatment forms)*	
	CM	*MM*
ECOG-ACRIN	Screening: OPEN checklist has a change Working on language to populate instructions field on 15 min delay for uploading Path and CLIA reports Treatment: Complete	Screening: Rave Forms – Forms are set Treatment: Forms are set but could be minor changes due to validation checks.
SWOG	Treatment: Completed but had to add consent questions outside of PMI Integrations.	
NRG	Treatment: entry forms are finalized in OPEN and Rave. Other forms are also built; still running validation checks.	**N/A**
Alliance	Completed FFP for A6	**N/A**
CCTG	**N/A**	
COG		**N/A**

Group Roadblocks

Group	5/31/2023 Mting	7/12/2023 Mting
ECOG-ACRIN	• Study build portion of E5 is on hold pending language on Cohort Migration; will wait to activate once Cohort Migration is implemented • MM Treatment Trial – Need the Treatment Assignments will work	• *Need the EC template*
SWOG	• EC v4 template; keeping MSRP on hold • MM Treatment Trial – Need the Treatment Assignments will work	• *Need v4 to complete study build for MM*
NRG	• N2 Study will require an update from Cohort Migration – How will this impact the current study..need the final language	• *Need more information on the OPEN process; will walk through the Cohort Migration workflow*
Alliance	• A2 and A3 need Cohort Migration • A6 does not need Cohort Migration so we can move forward on this study	• *Waiting for Cohort Migration Template – Is there anything the project team to provide to help prepare. Knowing what the variables are…will add that to next presentation*
CCTG	• EC v2 template; keeping MSRP on hold • Need patients for UAT testing	• *Same as last meeting*
COG	• No roadblocks	• *No Roadblocks*

PMI Project Discussion Items

Open Discussion

Next Steps

Next Steps

Next meeting will be on 7/26/2023 at 1:00pm EST

Agenda

- Role Call
- Project Status Update
- Group Status Update
- Review FAQs

Communication

Contact the PMI Mailbox for any PMI related questions & comments

pmistandards@nih.gov

The project team will respond within 48 hours with a response or a follow up

PMI Wiki

https://wiki.nci.nih.gov/display/CDISC/Precision+Medicine+Initiative

All presentations, recordings, minutes, project documents and releases will be posted on this wiki

NATIONAL CANCER INSTITUTE

www.cancer.gov

www.cancer.gov/espanol

Appendix

Target Timeline

Nov – Mid Dec 2022

Group Activities
- Develop Study-specific Rave CRFs

NCI Activities
- ComboMATCH UAT Matchbox Environment
- MyeloMATCH UAT Matchbox Environment
- MATCHBox & OPEN Integrations for UAT
- Prepare Beta Screening & Treatment ALS files

Mid Dec 2022

NCI Activities
- Release EC Templatev1
- Release Beta Screening Protocol ALS
- Release Beta Treatment Protocol ALS
- aMOI List Approval and MATCHBox Upload

Mid Dec to Jan 30, 2023

Group Activities
- UAT Testing

NCI Activities
- Iterative updates to test findings (show-stoppers)

Target Timeline

Jan 31, 2023

NCI Activities
- Release EC Template v1
- Release Prod Screening Protocol ALS
- Release Prod Treatment Protocol ALS
- Release Prod Central Study ALS
- Release NCI OPEN Integrations for Prod
- Release NCI Genexus Installation (MyeloMATCH)

Jan 31 to Feb 14, 2023

NCI + Group Activities
- Support Group Study Builds

Feb 14, 2023

NCI + Group Activities
- Launch BOTH Initiatives

Spring 2023

NCI Activities
- Release Additional ALS(s)

ComboMATCH Priority 1 List

Study #	Document Number	Document Title	Group	Current Status	Next Steps	Primary Agent Name (P) Other Agent Name (O)
1	EAY191	Molecular Analysis for Combination Therapy Choice (ComboMATCH)	ECOG-ACRIN	8/15/2022 Approval on Hold	Revision 3 back from CIRB with approval. On hold for DTL, funding sheet and IND filing.	
2	EAY191-N4	Molecular Analysis for Combination Therapy Choice (ComboMATCH) EAY191-N4: A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers A ComboMATCH Treatment Trial	NRG	8/15/2022 Approval on Hold	Revision 4 back from CIRB with approval. On hold for DTL, funding sheet and IND filing.	(P) Olaparib (AZD2281) (747856) (O) Selumetinib (AZD6244 hydrogen sulfate) (748727)
3	EAY191-E4	A ComboMATCH Treatment Trial ComboMATCH Treatment Trial E4: Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors	ECOG-ACRIN	8/26/2022 Approval on Hold	Revision 3 back from CIRB with approval. On hold for DTL, funding sheet and IND filing.	(P) Nilotinib (747599) (O) Paclitaxel (Taxol) (673089)
4	EAY191-N2	A ComboMATCH Treatment Trial EAY191-N2: Phase 2 Trial of Fulvestrant and Binimetinib in Patients with Hormone Receptor-Positive Metastatic Breast Cancer with a Frameshift or Nonsense Mutation or Genomic Deletion in NF1	NRG	8/26/2022 Approval on Hold	Revision 3 back from CIRB with approval. On hold for DTL, funding sheet and IND filing.	(P) Binimetinib (788187) (O) Fulvestrant (Faslodex) (719276)
5	EAY191-S3	Phase 2 Study of Paclitaxel + Ipatasertib in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors	SWOG	8/29/2022 Approval on Hold	Revision 4 back from CIRB with approval. On hold for DTL, funding sheet and IND filing.	(P) Ipatasertib (781451) (O) Paclitaxel (Taxol) (673089)

ComboMATCH Priority 2 List

Study #	Document Number	Document Title	Group	Current Status	Next Steps	Primary Agent Name (P) Other Agent Name (O)
6	EAY191-A6	A ComboMATCH Treatment Trial: FOLFOX in Combination with Binimetinib as 2nd Line Therapy for Patients with Advanced Biliary Tract Cancers with MAPK Pathway Alterations	Alliance	Approval on Hold 9/14/2022	Rev 4 approved by CIRB on 10/24. CTEP currently reviewing stips.	(P) Binimetinib (788187) (O) OXALIplatin (Eloxatin) (266046) (O) 5-Fluorouracil (5-FU) (19893) (O)Leucovorin calcium (3590)
7	EAY191-A3	Palbociclib and Binimetinib in RAS-Mutant Cancers	Alliance	Approval on Hold 8/26/2022	Rev 2 sent to CIRB . Reviewed on 10/6, study team responding to stips	(P) Palbociclib (PD-0332991) (772256) (O) Binimetinib (788187)

ComboMATCH Priority 3 List

Study #	Document Number	Document Title	Group	Current Status	Next Steps	Primary Agent Name (P) Other Agent Name (O)
8	EAY191-A2	Olaparib Plus Low-Dose Alpelisib for Breast Cancer	Alliance	In Review 4/4/2022	Rev 3 recv;d 10/19, currently with LR. Looks like it'll be another disapproval. Not yet sent to CIRB for initial review.	(P) Olaparib (AZD2281) (747856) (O) Alpelisib (BYL719) (801658)
9	EAY191-C1	Phase 2 Subprotocol of the Combination of a MEK Inhibitor and a Pan-RAF Inhibitor in Patients with Relapsed/Refractory Tumors Harboring Activating MAPK Pathway Mutations	COG	In Review 9/29/2022	Protocol reviewed at PRC 10/20; CR is being put together	(P) Selumetinib (AZD6244 hydrogen sulfate) (748727) (O) DAY101 (TAK-580, MLN-2480) (800798)
10	EAY191-E5	ComboMATCH Treatment Trial E5: A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors	ECOG-ACRIN	In Review 2/22/2022	Waiting for revision 2 since 9/28; reminder was sent to EA 10/24	(P) AMG 510 (Sotorasib) (825510) (O) Panitumumab (742319)
11	EAY191-N5	Molecular Analysis for Combination Therapy Choice (ComboMATCH) EAY191-N5: A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors A ComboMATCH Treatment Trial	NRG	In Review 11/22/2021	Rev 3 disapproval sent 10/15; waiting for Rev 4	(P) Neratinib (783782) (O) Palbociclib (PD-0332991) (772256)

MyeloMATCH Priority 1 List

Study #	Document Number	Document Title	Group	Current Status	Next Steps
1	MYELOMATCH	Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials	SWOG	11/12/2021: Approval on Hold	CIRB Reviewed on 9/15, version with stips under CTEP review now.
2	MM1YA-S01	A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) to (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, and Azacitidine + Venetoclax in Patients Aged 59 or Younger with High-Risk (Adverse) Acute Myeloid Leukemia; A MYELOMATCH Clinical Trial	SWOG	9/2/2022: Approval on Hold	CIRB Reviewed on 9/15, version with stips under CTEP review now.
3	MM1YA-CTG01	A Measurable Residual Disease (MRD) Driven, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH Clinical Trial	CCTG	9/2/2022: Approval on Hold	CIRB Review Oct 6, responding to stips
6	MM1OA-EA02 (Concept)	A Randomized Phase II Study of HMA-Based Therapies for the Treatment of Older Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia: A myeloMATCH Treatment Trial	ECOG-ACRIN	8/29/2022: Approved, no protocol yet	Waiting for protocol

MyeloMATCH Priority 2 List

Study #	Document Number	Document Title	Group	Current Status	Next Steps
4	MM2YA-EA01	Eradicating Measurable Residual Disease in Patients with Acute Myeloid Leukemia (AML) Prior to StEm Cell Transplantation (ERASE): A MyeloMATCH Treatment Trial	ECOG-ACRIN	1/21/2022: In Review	Reviewed by CIRB, responding to stips
5	MM1OA-S02	A Randomized Phase II Study of Targeted Agents with the Oral DNMT1 Inhibitor Cedazuridine-Decitabine (ASTX727) for the Treatment of Newly Diagnosed TP53-Mutated Acute Myeloid Leukemia in Older Patients: A myeloMATCH Treatment Trial	SWOG	10/17/2022: In Review	Scheduled for PRC 11/4
7	MM1MDS-EA03 (Concept	ERADICATE MDS with TP53 Study: Efficacy of taRgeted Agents Combinations with Oral DNMT1 Inhibitor C-DEC (ASTX727) for TrEatment of Higher Risk myElodysplastic Syndromes with TP53 Mutations: A Non-Comparative, Parallel, Multi-Arm Phase 2 Study	ECOG-ACRIN	8/12/2022: Approval on hold, waiting for drug commitment	W+A6:G8aiting for Astex commitment, Genentech has provided commitment on 10/20

Review Schemas

EAY191-N4


Protocol N4
EAY191-N4
People with:
• RAS Pathway Mutant (KRAS, NRAS, HRAS, NF1, BRAF)
• AND Ovarian (including primary peritoneal and fallopian tube) OR Endometrial Cancer
• Excludes:
◦ Prior MEK inhibitors
◦ Prior PARP inhibitors with disease progression (Prior PARP inhibitors are allowed if there was no disease progression)
Cohort 1
EAY191-N4.C1
People with Ovarian (including primary peritoneal and fallopian tube) Cancer
N = 85
Cohort 2
EAY191-N4.C2
People with Endometrial Cancer
N = 80
R
R
Treatment Regimen 1
EAY191-N4.C1.R1
(Selumetinib + Olaparib)
Treatment Regimen 2
EAY191-N4.C1.R2
(Selumetinib)
Participants on Treatment Regimen 2 that progress are eligible to crossover to Treatment Regimen 1 in the same Cohort
Treatment Regimen 1
EAY191-N4.C2.R1
(Selumetinib + Olaparib)
Treatment Regimen 2
EAY191-N4.C2.R2
(Selumetinib)
KEY
R
Randomization

EAY191-E4


Protocol E4
EAY191-E4
People with:
• Previous taxane therapy (metastatic setting)
• Excludes:
◦ Platinum-resistant epithelial serous ovarian cancer
◦ cKIT variants
◦ PDGFRA D842V variants
N = 40
Treatment Regimen 1
EAY191-E4.R1
(Nilotinib + Paclitaxel)

EAY191-N2- Draft



EAY191-S3


Protocol S3
EAY191-S3
People with:
• Advanced or metastatic non-breast solid tumors
• A mutation in AKT1/AKT2/AKT3
• Progressed on prior taxane therapy
Excludes:
• Mutations in KRAS, NRAS, HRAS or BRAF
• Prior AKT inhibitor
N = 33
Treatment Regimen 1
EAY191-S3.R1
(Paclitaxel + Ipatasertib)

MMIYA-CTG01 Draft